# PT-141 for low sexual desire in women: trial re-analysis

Source: https://pepvault.app/research/pt-141-spielmans-2021

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [PT-141](https://pepvault.app/research#pt-141)

Meta-analysis · people

# PT-141: side-effect dropouts far higher than placebo in re-analysis

Checked against the paper November 2026 Meta-analysis [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

This re-analysis of the main PT-141 trials in women with low sexual desire found modest benefits and much higher odds of quitting due to side effects than on placebo, and it concludes the drug is generally not useful.

- **Kind:** Meta-analysis
- **Studied in:** People
- **Published:** 2021
- **Journal:** J Sex Res

## What they tested

This re-analysis asked whether the published results of two Phase III bremelanotide trials for hypoactive sexual desire disorder (HSDD, persistently low sexual desire) in women gave a complete picture of benefit and harm.

## How the study was done

A single-author meta-analysis that pooled data from two 24-week Phase III trials, drawn from the FDA New Drug Application. It also compared the original published report against the trials' protocols.

<!--promo-->

PepVault for iPhone

## Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

Benefits were similar to the original report's, but the author judged them modest and measured on post hoc outcomes of questionable validity. Women on bremelanotide had much higher odds of leaving the trial because of side effects (odds ratio 11.98, 95% CI 3.74-38.37, number needed to harm 6). They were also less likely to both finish the trial and choose to join the open-label follow-up study (odds ratio 0.30, number needed to harm 4), which the author read as a preference for placebo. The original paper left out 72.72% of the outcomes listed in the protocols and presented 15 secondary measures the protocols never listed.

## What it doesn’t show

This is one author's re-analysis of two existing trials, not a new trial. Treating trial completion plus joining the follow-up study as a preference for placebo is an indirect measure.

## The paper

Spielmans Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. J Sex Res. 2021.

- [PubMed (PMID 33678061)](https://pubmed.ncbi.nlm.nih.gov/33678061/)
- [The paper (DOI 10.1080/00224499.2021.1885601)](https://doi.org/10.1080/00224499.2021.1885601)

## The compound

- [PT-141: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/pt-141)
- [PT-141 dose guide](https://pepvault.app/lab/dosage/pt-141)

## With this study

### PT-141

- [PT-141: the full reference](https://pepvault.app/peptides/pt-141)
- [PT-141 dose guide](https://pepvault.app/lab/dosage/pt-141)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pt-141-10mg)

### Studies

- [PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeks](https://pepvault.app/research/pt-141-clayton-2016)
- [PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety data](https://pepvault.app/research/pt-141-clayton-2022)
- [All 3 studies](https://pepvault.app/research#pt-141)

### Compared with

- [PT-141 vs Melanotan II](https://pepvault.app/peptides/compare/pt-141-vs-melanotan-ii)
- [PT-141 vs Oxytocin](https://pepvault.app/peptides/compare/pt-141-vs-oxytocin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)

## More studies on PT-141

- [PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeks](https://pepvault.app/research/pt-141-clayton-2016) Randomized trial · people · 2016
- [PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety data](https://pepvault.app/research/pt-141-clayton-2022) Systematic review · people · 2022
- [Every study on PT-141](https://pepvault.app/research#pt-141)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### PT-141

- [PT-141: the full reference](https://pepvault.app/peptides/pt-141)
- [PT-141 dose guide](https://pepvault.app/lab/dosage/pt-141)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pt-141-10mg)

### Studies

- [PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeks](https://pepvault.app/research/pt-141-clayton-2016)
- [PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety data](https://pepvault.app/research/pt-141-clayton-2022)
- [All 3 studies](https://pepvault.app/research#pt-141)

### Compared with

- [PT-141 vs Melanotan II](https://pepvault.app/peptides/compare/pt-141-vs-melanotan-ii)
- [PT-141 vs Oxytocin](https://pepvault.app/peptides/compare/pt-141-vs-oxytocin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)

<!--promo-->

PepVault for iPhone

## Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on PT-141](https://pepvault.app/research#pt-141)

## The library

- [PT-141](https://pepvault.app/peptides/pt-141)
- [PT-141 dose guide](https://pepvault.app/lab/dosage/pt-141)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
